Aldeyra Therapeutics, Inc.
$1.36
-$0.02 (-1.45%)
$1.34Day Range$1.40
Key Statistics
Market Cap
$82.04M
Shares Outstanding
60.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 2, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$1.40
Day High
$1.40
Day Low
$1.34
Volume
367.7K
VWAP
$1.37
Prev Close
$1.38
Transactions
--
Acc. Volume
--
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
PHARMACEUTICAL PREPARATIONSSIC 28346 employees131 HARTWELL AVENUE, LEXINGTON, MA, 02421781-761-4904IPO May 2, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001341235
- Composite FIGI
- BBG0029H8ZF6
- Share Class FIGI
- BBG0029H8ZG5
- Ticker Root
- ALDX
- SIC Code
- 2834
About Aldeyra Therapeutics, Inc. (ALDX) Stock
Aldeyra Therapeutics, Inc. (ALDX) closed the 2026-09-18 session at $1.36, down 1.45% versus the previous close (-0.02). The stock opened at $1.40 and traded between $1.34 and $1.40 during that session. Session trading volume was 368K shares. The volume-weighted average price (VWAP) is $1.37.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Aldeyra Therapeutics, Inc. has a market capitalization of $82.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ALDX is listed on the XNAS exchange. The company employs approximately 6 people. Aldeyra Therapeutics, Inc. is headquartered in LEXINGTON, MA. The recorded listing date is 2014-05-02.
On this page you can find market ALDX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.